Is Cardiol Therapeutics Stock a Good Investment?
Cardiol Therapeutics Investment Advice | CRDL |
- Examine Cardiol Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cardiol Therapeutics' leadership team and their track record. Good management can help Cardiol Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cardiol Therapeutics' business and its evolving consumer preferences.
- Compare Cardiol Therapeutics' performance and market position to its competitors. Analyze how Cardiol Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Cardiol Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cardiol Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cardiol Therapeutics Class stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cardiol Therapeutics Class is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cardiol Therapeutics Stock
Researching Cardiol Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.39. Cardiol Therapeutics had not issued any dividends in recent years.
To determine if Cardiol Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardiol Therapeutics' research are outlined below:
| Cardiol Therapeutics generated a negative expected return over the last 90 days | |
| Cardiol Therapeutics may become a speculative penny stock | |
| Cardiol Therapeutics has high historical volatility and very poor performance | |
| Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (28.13 K) with profit before overhead, payroll, taxes, and interest of 78.76 K. | |
| Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14. | |
| Cardiol Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: What is HC Wainwrights Forecast for CRDL FY2024 Earnings - MarketBeat |
Cardiol Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Cardiol Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cardiol Therapeutics Class. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardiol Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cardiol Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cardiol Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-17 | 2021-06-30 | -0.14 | -0.16 | -0.02 | 14 | ||
2019-05-08 | 2019-03-31 | -0.0676 | -0.0973 | -0.0297 | 43 | ||
2024-08-12 | 2024-06-30 | -0.13 | -0.1 | 0.03 | 23 | ||
2023-11-14 | 2023-09-30 | -0.12 | -0.09 | 0.03 | 25 | ||
2023-03-30 | 2022-12-31 | -0.15 | -0.12 | 0.03 | 20 | ||
2022-03-22 | 2021-12-31 | -0.14 | -0.11 | 0.03 | 21 | ||
2021-03-31 | 2020-12-31 | -0.12 | -0.15 | -0.03 | 25 | ||
2020-11-12 | 2020-09-30 | -0.0679 | -0.1013 | -0.0334 | 49 |
Know Cardiol Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cardiol Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardiol Therapeutics Class backward and forwards among themselves. Cardiol Therapeutics' institutional investor refers to the entity that pools money to purchase Cardiol Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 52.4 K | Bank Of Montreal | 2024-06-30 | 50.1 K | Bmo Capital Markets Corp. | 2024-06-30 | 50.1 K | Marble Harbor Investment Counsel, Llc | 2024-09-30 | 36.9 K | Sontag Advisory Llc | 2024-09-30 | 30.3 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 29.3 K | Group One Trading, Lp | 2024-06-30 | 28.3 K | Royal Bank Of Canada | 2024-06-30 | 27.1 K | Two Sigma Investments Llc | 2024-09-30 | 24.7 K | Tejara Capital Ltd | 2024-06-30 | 1.7 M | Advisorshares Investments, Llc | 2024-09-30 | 1.2 M |
Cardiol Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 132.2 M.Market Cap |
|
Cardiol Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (0.77) | (0.80) | |
| Return On Equity | (1.00) | (1.05) |
Determining Cardiol Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Cardiol Therapeutics is a good buy. For example, gross profit margin measures Cardiol Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cardiol Therapeutics' profitability and make more informed investment decisions.
Evaluate Cardiol Therapeutics' management efficiency
Cardiol Therapeutics has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0844) %, meaning that it created substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.81. The value of Return On Capital Employed is expected to slide to -1.1. At this time, Cardiol Therapeutics' Total Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 610.6 K this year, although the value of Non Currrent Assets Other are projected to rise to (0.95).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.64 | |
| Tangible Book Value Per Share | 0.43 | 0.63 | |
| Enterprise Value Over EBITDA | (1.26) | (1.32) | |
| Price Book Value Ratio | 2.51 | 2.38 | |
| Enterprise Value Multiple | (1.30) | (1.36) | |
| Price Fair Value | 2.51 | 2.38 | |
| Enterprise Value | 37.2 M | 60.6 M |
Management at Cardiol Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.697 |
Basic technical analysis of Cardiol Stock
As of the 26th of November, Cardiol Therapeutics shows the Standard Deviation of 3.71, risk adjusted performance of (0.05), and Mean Deviation of 2.87. Cardiol Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cardiol Therapeutics information ratio and potential upside to decide if Cardiol Therapeutics is priced correctly, providing market reflects its regular price of 1.54 per share. Please also double-check Cardiol Therapeutics Class jensen alpha, which is currently at (0.37) to validate the company can sustain itself at a future point.Cardiol Therapeutics' Outstanding Corporate Bonds
Cardiol Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cardiol Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cardiol bonds can be classified according to their maturity, which is the date when Cardiol Therapeutics Class has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Cardiol Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cardiol Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.37) | |||
| Mean Deviation | 2.87 | |||
| Coefficient Of Variation | (1,355) | |||
| Standard Deviation | 3.71 | |||
| Variance | 13.77 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.38) | |||
| Maximum Drawdown | 19.95 | |||
| Value At Risk | (5.73) | |||
| Potential Upside | 5.62 | |||
| Skewness | 0.5126 | |||
| Kurtosis | 0.9363 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.37) | |||
| Mean Deviation | 2.87 | |||
| Coefficient Of Variation | (1,355) | |||
| Standard Deviation | 3.71 | |||
| Variance | 13.77 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.38) | |||
| Maximum Drawdown | 19.95 | |||
| Value At Risk | (5.73) | |||
| Potential Upside | 5.62 | |||
| Skewness | 0.5126 | |||
| Kurtosis | 0.9363 |
Consider Cardiol Therapeutics' intraday indicators
Cardiol Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cardiol Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 29850.7 | |||
| Daily Balance Of Power | (0.62) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 1.58 | |||
| Day Typical Price | 1.56 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.08) |
Cardiol Stock media impact
Far too much social signal, news, headlines, and media speculation about Cardiol Therapeutics that are available to investors today. That information is available publicly through Cardiol media outlets and privately through word of mouth or via Cardiol internal channels. However, regardless of the origin, that massive amount of Cardiol data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cardiol Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cardiol Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cardiol Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cardiol Therapeutics alpha.
Cardiol Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cardiol Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cardiol Therapeutics Corporate Management
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA BSCPT | Vice Development | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cardiol Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.